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Abstract
Objectives—Piperacillin is often used in preterm infants for intra-abdominal infections;
however, dosing has been derived from small single-center studies excluding extremely preterm
infants at highest risk for these infections. We evaluated the population pharmacokinetics (PK) of
piperacillin using targeted sparse sampling and scavenged samples obtained from preterm infants
≤32 weeks gestational age at birth and <120 postnatal days.
Materials and Methods—A 5-center study was performed. A population PK model using
nonlinear mixed effect modeling was developed. Covariate effects were evaluated based on
estimated precision and clinical significance.
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Results—Fifty-six preterm infants were evaluated and had a median (range) gestational age at
birth of 25 (22–32) weeks, a postnatal age of 17 (1–77) days, a postmenstrual age of 29 (23–40)
weeks, and a weight of 867 (400–2580) grams. The final PK data set contained 211 samples;
202/211 (96%) were scavenged from discarded clinical specimens. Piperacillin population PK was
best described by a 1-compartment model. The population mean clearance (CL) was derived by
the equation CL (liter/h)=0.479 x (weight)0.75 x 0.5/serum creatinine and using a volume of
distribution (V) (liter) of 2.91 x (weight). The relative standard errors around parameter estimates
ranged from 13.7–32.2%. A trend towards increased CL was observed with increasing gestational
age at birth; infants with serum creatinine ≥1.2 mg/dL had a 60% reduction in piperacillin CL. The
majority (>70%) of infants did not meet pre-defined pharmacodynamic efficacy targets.
Conclusions—Scavenged PK sampling is a minimal-risk approach that can provide meaningful
information related to development of PK models but not dosing recommendations for
piperacillin. The utility of scavenged sampling in providing definitive dosing recommendations
may be drug-dependent and needs to be further explored.
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Piperacillin is a semisynthetic derivative of ampicillin with a ureido and piperazine side
chain.1 The combination of piperacillin with tazobactam (beta-lactamase inhibitor) is
approved by the U.S. Food and Drug Administration (FDA) for the treatment of children >2
months of age with appendicitis or peritonitis. The European Medicines Agency has
approved the combination for the treatment of complicated intra-abdominal infections in
children 2–12 years of age. Safety, efficacy, and dosing recommendations for infants <2
month of age have not been established. In adults and older children, more than 70% of
piperacillin is primarily excreted unchanged in the urine. Total body clearance increases and
elimination half-life decreases with increasing age.2,3 After intravenous administration, the
elimination half-life of piperacillin in adults and children 2–12 years of age is short (0.5–1
hour); elimination half-life is prolonged in children and infants <23 months of age (0.9–1.4
hours).2,3
In infants <2 months of age, piperacillin-tazobactam is commonly used “off label” for the
treatment of intra-abdominal infections, such as necrotizing enterocolitis, as well as severe
infections due to bacterial resistance. Appropriate dosing recommendations for this
population have been limited by single-center studies and exclusion of the most preterm
(<28 weeks gestational age at birth) infants.4 Because the main clearance mechanism for
piperacillin is the renal system, ontogenic pharmacokinetic (PK) changes in the developing
infant are expected. Extrapolation of PK data from more mature infants is often difficult due
to non-linear relationships between maturation and renal function.5 PK studies are needed in
preterm infants to appropriately describe drug disposition in this population.
PK studies are rarely conducted in infants due to the research challenges posed by this
population in the context of traditional study design. These challenges include limited blood
volume for PK sampling, difficulty in obtaining PK samples due to the critical medical
condition of the infants, and low parental informed consent rates. As such, investigators
have explored novel minimal-risk methods to evaluate the PK of antimicrobials in this
population. One approach is the use of scavenged samples, left over from the normal clinical
care of infants. When combined with the collection of timed PK samples (collected
specifically for study purposes), scavenged samples have allowed for characterization of the
PK in preterm infants.6 Our research team has recently demonstrated the utility of this
approach to describe the PK of metronidazole in premature infants.7 However, to our
knowledge, the use of scavenged samples for PK analysis of other antimicrobials has not
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been evaluated. The present study was conducted to assess the population PK of intravenous




Pharmacokinetic samples for this analysis were obtained from the Antimicrobial PK in
High-Risk Infants trial sponsored by the Pediatric Pharmacology Research Unit. This multi-
center, prospective, open-label PK study of commonly used antimicrobial agents in the
neonatal intensive care unit enrolled infants ≤32 weeks gestational age at birth who were
<120 days old and who were receiving intravenous piperacillin or piperacillin-tazobactam
per routine medical care. Piperacillin dosing was determined by the routine clinical practice
in each unit, and no exclusion criteria were used. Infants were stratified by birth gestational
age (BGA) at enrollment: <26 weeks, 26–29 weeks, and 30–32 weeks. The study was
approved by the institutional review boards at each institution, and informed consent was
obtained prior to enrollment.
The following information was collected for covariate analysis: BGA, postnatal age (PNA),
postmenstrual age (PMA), weight, sex, race, serum creatinine, and ethnicity. Covariates that
exhibited time-dependent changes (e.g., weight, PNA) were permitted to change with time,
and the actual value in the data set reflects the observations made at each patient visit.
Missing weights were imputed with the last recorded value carried forward for up to 7 days.
Serum creatinine (SCR) was recorded when obtained for clinical care. Missing SCR values
were imputed based on an exponential model of SCR and PMA derived from the data.
PK Sample Collection
A sparse sampling approach was followed in this study. Samples were divided into 2 types:
scavenged and blood draw. Scavenged samples were defined as samples obtained without
obtaining additional blood from the infant. These samples were collected from the clinical
laboratory from discarded blood (heparinized or ethylenediaminetetraacetic acid [EDTA]
tubes) obtained for routine clinical care. Blood draw samples were defined as samples
obtained with collection of extra blood from the infant. Each blood draw was approximately
0.3 mL of blood collected in EDTA Microtainers. PK sample collection was planned at the
following time points: immediately prior to piperacillin infusion, immediately after the
completion of infusion (t=0), approximately 1 hour after completion of infusion (t=1 hour),
approximately 2 hours after completion of infusion (t=2 hours), and immediately prior to
infusion of the next dose. The duration of piperacillin infusion was performed according to
routine clinical care at the site. Samples were refrigerated or placed on ice immediately after
collection and then centrifuged at 1500 g and 4°C for 10 minutes. Plasma was removed and
stored at −70° C. Samples from all sites were shipped on dry ice to Duke University Medical
Center where they were stored at −70° C prior to analysis. Samples were stored for a
maximum of 32 months prior to analysis.
Bioanalytical Assay
A liquid chromatography-tandem mass spectrometry (HPLC/MS/MS) assay for piperacillin
detection in human plasma suitable for small plasma volumes was developed and validated.
Sample analysis was performed on a triple quadrupole mass spectrometer API 4000
(Applied Biosystems–ABSciex, Foster City, CA, USA) operated with electrospray
ionization (TurboV source using a TurboIonspray® probe). Instrument parameters were
optimized for the piperacillin transition (518.2→143.2 m/z). Ionspray voltage and turbo
heater temperature were kept at 2500 V and 500° C, respectively; a collision gas of 10 and a
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collision energy of 25 V were used. Piperacillin and dicloxacillin (internal standard [IS])
were purchased from the Sigma Chemical Company (St. Louis, MO, USA). HPLC
separation was achieved using a reverse-phase C18 Aquasil column (Thermo Fisher,
Waltham, MA, USA) with a flow-rate of 0.75 ml/min using a gradient mobile phase. Mobile
phase A consisted of 0.1% formic acid in water, and mobile phase B consisted of 0.1%
formic acid in methanol. Total run time was 6 minutes. Analytical data were acquired by
Analyst Software 1.4.1 (Applied Biosystems–ABSciex, Foster City, CA, USA). The lower
limit of quantitation of piperacillin in plasma was 0.3 mg/L. Intraday and interday
coefficients of variation were <7% at concentrations ranging from 0.3–120 mg/L.
Population PK Analysis
PK data were analyzed with a nonlinear mixed effect modeling (NONMEM) approach using
the computer program NONMEM (version 7) in conjunction with WINGS for NONMEM
version 7.03 (Auckland, NZ). Output was summarized using STATA 10 (College Station,
TX, USA). The first-order conditional estimation method with interaction was used for all
model runs. One- and 2-compartment structural PK models were evaluated. Inter-individual
(IIV) random effects were evaluated on clearance (CL) and volume of distribution (V).
Covariance was described by a block Omega matrix. An exponential model for IIV variance
for CL and V was used, and a proportional error model was deemed appropriate to describe
residual variability. The potential impact of clinical covariates on PK parameters was
explored if a relationship was suggested by visual inspection of scatter and box plots
(continuous and categorical variables, respectively) of individual Bayesian estimates
obtained from the base model and IIV (ETAs) against covariates. The following covariates
were evaluated: weight (kg), BGA (weeks), PNA (days), PMA (defined as BGA plus PNA
in weeks [PNA/7]), SCR, race, sex, and ethnicity. Once covariates were identified during the
model-building process, covariate testing was performed via standard forward addition
backward elimination methods. Potential covariates that reduced the objective function by
more than 3.84 (P<~0.05) were included in the subsequent multivariable analysis. A forward
inclusion with backwards elimination approach was used during the multivariable step, and
a reduction of 6.63 (P<~0.01) was required for retention of a covariate in the final model.
Continuous covariates were scaled to their median values. Empirical Bayesian estimates of
individual infant PK parameters were generated from the final model using the post-hoc
subroutine.
Model Evaluation
Models were evaluated based on successful minimization, goodness-of-fit plots, precision of
parameter estimates, bootstrap procedures, and standardized visual predictive check. The
precision of the final population PK model parameter estimates was evaluated using non-
parametric bootstrapping (1000 replicates) to generate the 95% confidence intervals (CIs)
for parameter estimates. For the standardized visual predictive check, the final model was
used to generate 1000 Monte Carlo simulation replicates per time point of piperacillin
exposure. Simulated results were compared at the subject level with those observed in the
study by calculating and plotting the percentile of each observed concentration in relation to
its 1000 simulated observations derived from the final model.8 The dosing and covariate
values used to generate the predictions in the standardized visual predictive check were the
same as those used in the study population. The number of observed concentrations outside
of the 90% prediction interval for each time point was quantified.
Assessment of Dose-exposure Relationship
Piperacillin demonstrates time-dependent pharmacodynamics (PD). For target exposure, we
chose the time above a minimum inhibitory concentration (MIC) of 16–64 mg/L at steady
state. This MIC target is consistent with the Clinical and Laboratory Standards Institute-
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recommended MIC susceptibility breakpoint of piperacillin/tazobactam for enteric gram-
negative organisms such Escherichia coli and Enterobacter sp. (16 mg/L) and Pseudomonas
aeruginosa (64 mg/L).9 Monte Carlo simulations using the final population PK model were
used to explore dose-exposure relationships using these defined targets. Commonly used and
current piperacillin dosing recommendations listed in Neofax10 and The Harriet Lane
Handbook11 were used in these simulated datasets to evaluate target attainment rates at
steady state. When a dosing range was recommended, the highest end of the range was
chosen for the simulations. Target attainment rates were calculated for infants who achieved
target piperacillin concentrations for 50% or 75% of the dosing interval. Inclusion of the
more stringent PD target criteria (75% of the dosing interval) was derived from the
assumption of an immuno-compromised state of preterm infants and the need to achieve
higher drug concentrations to achieve bacterial killing.
RESULTS
Study Population
A total of 77 subjects from 5 centers were evaluated for analysis. Subjects were excluded
from the analysis if dosing, concentration, or sampling data were unreliable (i.e., unable to
discern time when sample was collected relative to dose administered) (N=13) and if
sampling was obtained during line flush or during drug infusion and no other samples were
collected (N=8). The exclusion of these subjects and samples resulted in 56 subjects from 5
sites with 211 concentrations used in the modeling process. The overall median (range)
BGA, PNA, PMA, weight, serum creatinine, and dose were 25 (22–32) weeks, 17 (1–77)
days, 29 (23–40) weeks, 867 (400–2580) g, 0.8 (0.2–2.4) mg/dL, and 88 (39–147) mg/kg,
respectively (Table 1). The majority of subjects were male (31/56, 56%) and white (29/56,
52%), and few were Hispanic (5/56, 9%).
PK Specimens
A total of 41/261 (16%) outlier drug concentrations were removed from the analysis due to
unreliability of sampling times related to time of infusion (N=18), time of flush (N=20), or
sample contamination (N=3). Six of these samples did not have any measurable piperacillin
concentrations. The median time of PK sampling was 4.7 (0–11.16) hours after the dose, and
the median concentration was 25.6 (0.041–502) mg/L. An average of 3.7 samples per infant
(range, 1–22) was collected, and the overwhelming majority of PK samples were scavenged
from the clinical laboratory (202/211, 96%). Sixteen samples (16/211, 7.6%) had
concentrations below the limit of quantitation; 6/211 (2.8%) had a reliable signal above
background noise documented on the LC/MS/MS instrument, and this measurement was
used in the PK analysis. A value of zero was assigned to the remaining samples (10/211
[4.7%]) as they were below the level of detection.
Population PK Model Building
A 1-compartment model was the appropriate structural PK model for this data set (Figure 2).
Because few samples were obtained within the first few hours post dose, it was not possible
to estimate inter-compartmental clearance, and a 2-compartment model did not provide a
better fit to the data. Weight was included in the base CL and V models (Table 2).
Allometric scaling (Weight0.75) as well as estimation of the body size exponent (Weightθ)
were explored as potential body size models for CL and V. The exponent estimates for CL
and V were 0.62 and 0.86, respectively. However, given strong physiologic basis and no
improvement in model fit, exponents for weight were fixed at 0.75 and 1 for CL and V,
respectively. In the base model, scatter plots showed a correlation between IIV on CL
(ETA1) and V (ETA2); a covariance term was added to the model. Age- and maturity-
related covariates (BGA, PMA, PNA), as well as SCR, showed correlation with unexplained
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CL (ETA1) IIV (Figure 1). During the univariable evaluation (after inclusion of body
weight), all age-related covariates resulted in a significant decrease in the objective function
value (OFV); however, the largest drop in OFV occurred when SCR was added to the model
(Table 2). A SCR power model with exponent estimation did not improve the goodness of
fit. CL estimated by SCR was superior to age-related models, and the addition of a
maturation covariate (PMA) in the multivariable analysis did not improve the model
goodness of fit (Tables 2 and 3). No other covariates were evaluated in the V model due to
lack of correlation observed between the covariate and unexplained V (ETA2) IIV. Due to
the low number of blood draw samples, bias introduced by scavenged specimen collection
compared with timed blood draws around the dose could not be assessed.
Population PK Model Evaluation
The final model had good precision as evidenced by relative standard errors around the
parameter point estimates of 13.7–32.2% and by 95% confidence intervals generated by
bootstrapping (N = 1000 simulated trials, 981 successful runs) (Table 3). Larger relative
standard errors were observed for the point estimates of V. Goodness-of-fit diagnostic plots
for the final model are shown in Figure 2. The standardized visual predictive check revealed
a good fit between observed and predicted piperacillin concentrations as evidenced by the
uniform distribution of calculated observation percentiles for each time point (Figure 3). In
addition, only 8.5% (18/211) of observed concentrations were outside of the 90% prediction
interval.
Bayesian Estimates of CL, V, and Elimination Half-life
The median individual empirical Bayesian estimates for CL, V, and half-life were
summarized by gestational age group (Table 4). There was a trend towards increasing
median piperacillin weight-normalized CL with increasing BGA that was more apparent
between infants <26 weeks BGA and infants 26–29 weeks BGA. Weight-adjusted
piperacillin CL decreased with increasing SCR and, expectedly, did not change with
increasing body weight (Figure 4). Infants with SCR ≥1.2 mg/dL had a 60% lower CL
value. Half-life decreased with increasing BGA group.
Dose-exposure Relationship
High failure rates were calculated when the surrogate PD targets of time above MIC of 16
and 64 mg/L for 50% and 75% of the dosing interval were evaluated. Only 60% of all
infants achieved piperacillin concentrations >16 mg/L for 50% of the dosing interval. Only
30% of infants ≤29 weeks and none of those 30–32 weeks BGA achieved piperacillin
concentrations >64 mg/L for 50% of the dosing interval (Figure 5). When the same targets
were evaluated for 75% of the dosing interval, 50% of all infants achieved piperacillin
concentrations >16 mg/L; 15% of infants ≤29 weeks and none of those 30–32 weeks BGA
achieved piperacillin concentrations >64 mg/L for 75% of the dosing interval. Monte Carlo
simulations using the final population PK model were used to explore dose-exposure
relationships using current piperacillin dosing recommendations. Overall, dosing
recommendations by Neofax (100 mg/kg every 8–12 hours) and The Harriet Lane
Handbook (75 mg/kg every 8–12 hours) produced similar piperacillin exposures in
simulated datasets; only 40–60% of infants across BGA achieved the PD target of
concentrations above 16 mg/L for 50% of the dosing interval. Piperacillin concentrations
>64 mg/L for 75% of the dosing interval were achieved in the minority of simulated patients
(<25%); this finding was most pronounced among infants 30–32 weeks BGA (Figure 5).
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Most antimicrobial products used in preterm infants lack some aspect of PK information
specific to this population. Without appropriate studies specifically designed for preterm
infants, clinicians are often forced to prescribe products “off-label,” exposing patients to
potential adverse drug effects or less-than-optimal drug exposure without dosing
evidence.12,13
The primary goal was to evaluate the PK of piperacillin in this population, evaluate potential
covariates that would explain inter-individual variability in PK parameters, and assess the
potential bias introduced by scavenged sampling compared with traditional sampling per
study protocol. A population PK approach allowed for the use of sparse sampling, and
stratified enrollment ensured a broad distribution of BGA and PNA.
In the present model, piperacillin CL increased with allometrically scaled body weight, and
it decreased proportionally with increasing SCR. Allometric size adjustments in PK
parameters have been well established as appropriate and physiologic-based models to
describe CL changes among neonates and preterm infants.6,14 The association of CL with
SCR is expected due to the high proportion (>70%) of piperacillin excreted in the urine.3
However, the clinical utility of SCR in preterm infants during the first few days of life is
debated due to the confounding effect of maternal creatinine. Because only 3 (5%) of
subjects in this study were <3 days of life, it is unlikely that bias was introduced by maternal
creatinine contamination. The addition of maturational components (i.e., BGA, PNA, PMA)
into the multivariable CL model did not change the goodness of fit nor did it explain
remaining IIV. Due to ontogenic changes in renal function among preterm infants, SCR is
strongly linked with maturational components such as BGA, PNA, and PMA. A correlation
matrix between covariates included in this study revealed this association. This observation
likely prevented the ability to discern the effect of each maturational component in CL IIV
from SCR in the CL model-building process. Weight was the only covariate that explained
V IIV, consistent with other studies in preterm infants.14
The population PK model developed performed well and showed good precision around
parameter estimates. A high degree of IIV in CL (91.5% coefficient of variation [CV]), V
(119 CV%), and residual variability (RV, 73.8 CV%) was observed. The large IIV in CL
and V could have resulted from the diversity of study subjects included in this trial.
However, large unexplained IIV in CL and V remained in the final model after inclusion of
significant covariates. Because study efficiency was an important part of the study design,
data collection (demographics and other clinically relevant covariates) was limited. The
unexplained IIV could be attributed to other covariates not included in the study (i.e.,
concomitant medications). The large RV observed could be the result of several factors,
such as documentation errors in sampling or dosing times, model misspecification, and drug
degradation in scavenged samples. Ambient and refrigerator storage may affect piperacillin
stability in plasma.15,16 Information regarding the duration and conditions under which the
samples remained in the clinical laboratory before freezing were not collected, which limits
our ability to assess the reliability of drug concentrations in scavenged samples. Because
very few samples were drawn specifically for the study, the comparison between traditional
and scavenged sampling schemes was not possible. Large RV was unlikely to be the result
of drug concentration measurements given that the assay was validated according to FDA
criteria.17
Because this study did not evaluate efficacy or clinical outcomes, surrogate piperacillin PD
end points were used for the study population receiving piperacillin per routine clinical care
and in simulated datasets including current dosing recommendations from commonly used
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pediatric resources.10,11 The proportion of patients achieving surrogate PD targets for
efficacy was suboptimal. A substantial proportion of subjects (~40%) did not achieve
piperacillin concentrations efficacious against common gram-negative enteric bacteria (i.e.
Escherichia coli, enterobacter), and the vast majority (~70%) did not achieve concentrations
above the susceptibility breakpoint for more resistant organisms such as Pseudomonas
aeruginosa. A similar pattern was observed among simulated datasets using current dosing
recommendation guidelines. Dosing by Neofax or The Harriet Lane Handbook resulted in
similar target attainment rates, but similar to targets in the actual patient population,
outcomes were suboptimal. These findings could suggest that current dosing per standard of
care or as recommended in common pediatric resources is inadequate for this patient
population. However, this should be interpreted with caution because lower (2–10 fold) than
previously observed piperacillin concentrations2,4 were observed in this study, possibly as a
result of scavenged sampling.
Our understanding of the PK of piperacillin in preterm infants is extremely limited. A
single-center, single-dose PK study of piperacillin (75 mg/kg) conducted in 28 newborn
infants with BGA of 29–40 weeks and PNA of 3–11 days demonstrated an increase in
clearance with increasing gestational age.4 This study, however, excluded neonates <28
weeks estimated gestational age and infants beyond the second week of life. It is therefore
difficult to compare our study results to this prior study, but overall the individual empirical
Bayesian CL and V estimates of the present study were higher (2–10 fold) than previously
reported after controlling for BGA and PMA. V estimates were particularly large when
compared with other patient populations including older infants and adults.2,3 A large
piperacillin V would be expected in preterm infants due to the high total water content
relative to body mass18 and the hydrophilic nature of the drug. Alternatively, higher than
expected CL and V estimates are likely the result of low piperacillin concentrations
encountered in this trial. As mentioned, drug degradation in scavenged samples may have
accounted for the low concentrations observed.
In summary, minimal-risk methods such as scavenged PK sampling can provide meaningful
information related to development of structural PK models, as well as potential covariates
that explain IIV in PK parameters. After allometric scaling, incorporating SCR as a CL
model increased the model fit, and dose adjustments will likely be needed based on this
parameter. The utility of scavenged sampling in providing dosing recommendations,
however, is drug-dependent and likely not useful for unstable drugs such as piperacillin
without stringent criteria regarding handling or documentation of handling to eliminate
degraded samples from analysis. Future efforts evaluating this methodology should consider
the physicochemical properties of the drug, more detailed documentation of sample
collection and storage conditions, and simultaneous collection of traditional plasma samples
to fully assess the extent of bias introduced by scavenged sampling. Results from a follow-
up study (clinicaltrials.gov # NCT00873327) will further evaluate these findings.
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Base model scatter plots of CL ETA1 estimates and the following: BGA (A), PNA (B),
PMA (C), and SCR (D).
Cohen-Wolkowiez et al. Page 10














Final population pharmacokinetic model diagnostic plots: observed vs. population prediction
(A) and individual prediction (B), weighted residuals vs. population predictions (C) and
time (D). For A and B, the line of identity is included as a reference. For weighted residuals,
a solid line at y=0 is included as a reference.
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Standardized visual predictive check of piperacillin observation percentiles versus time after
last dose. Solid black circles represent calculated percentiles. Dashed lines represent the 5th,
50th, and 95th percentiles (bottom, middle, and top, respectively) of model predicted data.
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Weight-normalized piperacillin clearance versus serum creatinine (A) and body weight (B).
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Pharmacodynamic target attainment rates by gestational age group. A: Proportion of patients
who met PD target of desired concentrations for 50% of the dosing interval (black bar: 16
mg/L, gray bar: 64 mg/L); B: Proportion of patients who met PD target of desired
concentrations for 75% of the dosing interval (black bar: 16 mg/L, gray bar: 64 mg/L); C:
Proportion of simulated patients who met PD target of desired concentrations for 50% of the
dosing interval (dark blue bar: Neofax 16 mg/L, light blue bar: Neofax 64 mg/L, dark gray
bar: The Harriet Lane Handbook 16 mg/L, light gray bar: The Harriet Lane Handbook 64
mg/L); D: Proportion of simulated patients who met PD target of desired concentrations for
75% of the dosing interval (dark blue bar: Neofax 16 mg/L, light blue bar: Neofax 64 mg/L,
dark gray bar: The Harriet Lane Handbook 16 mg/L, light gray bar: The Harriet Lane
Handbook 64 mg/L).
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